Skip to main content
Top
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Systematic review of model-based cervical screening evaluations

Authors: Diana Mendes, Iren Bains, Tazio Vanni, Mark Jit

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Optimising population-based cervical screening policies is becoming more complex due to the expanding range of screening technologies available and the interplay with vaccine-induced changes in epidemiology. Mathematical models are increasingly being applied to assess the impact of cervical cancer screening strategies.

Methods

We systematically reviewed MEDLINE®, Embase, Web of Science®, EconLit, Health Economic Evaluation Database, and The Cochrane Library databases in order to identify the mathematical models of human papillomavirus (HPV) infection and cervical cancer progression used to assess the effectiveness and/or cost-effectiveness of cervical cancer screening strategies. Key model features and conclusions relevant to decision-making were extracted.

Results

We found 153 articles meeting our eligibility criteria published up to May 2013. Most studies (72/153) evaluated the introduction of a new screening technology, with particular focus on the comparison of HPV DNA testing and cytology (n = 58). Twenty-eight in forty of these analyses supported HPV DNA primary screening implementation. A few studies analysed more recent technologies - rapid HPV DNA testing (n = 3), HPV DNA self-sampling (n = 4), and genotyping (n = 1) - and were also supportive of their introduction. However, no study was found on emerging molecular markers and their potential utility in future screening programmes. Most evaluations (113/153) were based on models simulating aggregate groups of women at risk of cervical cancer over time without accounting for HPV infection transmission. Calibration to country-specific outcome data is becoming more common, but has not yet become standard practice.

Conclusions

Models of cervical screening are increasingly used, and allow extrapolation of trial data to project the population-level health and economic impact of different screening policy. However, post-vaccination analyses have rarely incorporated transmission dynamics. Model calibration to country-specific data is increasingly common in recent studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane M, 30 Suppl. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine. 2012;5:1–11.CrossRef Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane M, 30 Suppl. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine. 2012;5:1–11.CrossRef
2.
go back to reference Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.CrossRefPubMed Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.CrossRefPubMed
3.
go back to reference Cuzick J, Bergeron C, von Knebel DM, Gravitt P, Jeronimo J, Lorincz AT. New technologies and procedures for cervical cancer screening. Vaccine. 2012;30 Suppl 5:F107–16.CrossRefPubMed Cuzick J, Bergeron C, von Knebel DM, Gravitt P, Jeronimo J, Lorincz AT. New technologies and procedures for cervical cancer screening. Vaccine. 2012;30 Suppl 5:F107–16.CrossRefPubMed
4.
go back to reference Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008;26:A16–23.CrossRefPubMed Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008;26:A16–23.CrossRefPubMed
5.
go back to reference Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 2006;24 Suppl 3:S3–70. Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 2006;24 Suppl 3:S3–70.
6.
go back to reference Prorok PC. Mathematical models and natural history in cervical cancer screening. IARC Sci Publ. 1986;76:185–98.PubMed Prorok PC. Mathematical models and natural history in cervical cancer screening. IARC Sci Publ. 1986;76:185–98.PubMed
7.
go back to reference Van Oortmarssen GJ, Boer R, Habbema JD. Modelling issues in cancer screening. Stat Methods Med Res. 1995;1:33–54.CrossRef Van Oortmarssen GJ, Boer R, Habbema JD. Modelling issues in cancer screening. Stat Methods Med Res. 1995;1:33–54.CrossRef
8.
go back to reference Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer: A review of recent modelling studies. Eur J Health Econ. 2005;1:30–7.CrossRef Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer: A review of recent modelling studies. Eur J Health Econ. 2005;1:30–7.CrossRef
9.
go back to reference Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care. 2008;2:184–92.CrossRef Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care. 2008;2:184–92.CrossRef
10.
go back to reference Nahvijou A, Hadji M. A Systematic Review of Economic Aspects of Cervical Cancer Screening Strategies Worldwide: Discrepancy between Economic Analysis and Policymaking. Asian Pacific J. 2014;15:8229–37. Nahvijou A, Hadji M. A Systematic Review of Economic Aspects of Cervical Cancer Screening Strategies Worldwide: Discrepancy between Economic Analysis and Policymaking. Asian Pacific J. 2014;15:8229–37.
11.
go back to reference Esselen M, Feldman S. Cost effectiveness of Cervical cancer Prevention. Clin Obstet Gynecol. 2013;56:55–64.CrossRefPubMed Esselen M, Feldman S. Cost effectiveness of Cervical cancer Prevention. Clin Obstet Gynecol. 2013;56:55–64.CrossRefPubMed
12.
go back to reference Centre for Reviews and Dissemination: Systematic Reviews. CRD’s Guidance for Undertaking Reviews in Health Care. CRD: University of York; 2009. p. 292. Centre for Reviews and Dissemination: Systematic Reviews. CRD’s Guidance for Undertaking Reviews in Health Care. CRD: University of York; 2009. p. 292.
13.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009, 6(7). Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009, 6(7).
18.
go back to reference Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99:230–8.CrossRefPubMedPubMedCentral Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99:230–8.CrossRefPubMedPubMedCentral
19.
go back to reference Campos NG, Kim JJ, Castle PE, Ortendahl JD, O’Shea M, Diaz M, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2012;130(11):2672–84.CrossRefPubMed Campos NG, Kim JJ, Castle PE, Ortendahl JD, O’Shea M, Diaz M, et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer. 2012;130(11):2672–84.CrossRefPubMed
20.
go back to reference Ginsberg GM, Edejer TT-T, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer: a global and regional generalized cost-effectiveness analysis. Vaccine. 2009;27(43):6060–79.CrossRefPubMed Ginsberg GM, Edejer TT-T, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer: a global and regional generalized cost-effectiveness analysis. Vaccine. 2009;27(43):6060–79.CrossRefPubMed
21.
go back to reference Fetters MD, Lieberman RW, Abrahamse PH, Sanghvi RV, Sonnad SS. Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis. 2003;7:194–202.CrossRefPubMed Fetters MD, Lieberman RW, Abrahamse PH, Sanghvi RV, Sonnad SS. Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis. 2003;7:194–202.CrossRefPubMed
22.
go back to reference Willis BH, Barton P, Pearmain P, Bryan S, Hyde C. Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. Health Technol Assess. 2005;9(13). Willis BH, Barton P, Pearmain P, Bryan S, Hyde C. Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. Health Technol Assess. 2005;9(13).
23.
go back to reference Taylor LA, Sorensen SV, Ray NF, Halpern MT, Harper DM. Cost-effectiveness of the conventional Papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med. 2000;9:713–21.CrossRefPubMed Taylor LA, Sorensen SV, Ray NF, Halpern MT, Harper DM. Cost-effectiveness of the conventional Papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med. 2000;9:713–21.CrossRefPubMed
24.
go back to reference Shi J-FF, Canfell K, Lew J-BB, Zhao F-HH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239.CrossRefPubMedPubMedCentral Shi J-FF, Canfell K, Lew J-BB, Zhao F-HH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239.CrossRefPubMedPubMedCentral
25.
go back to reference Levin CE, Sellors J, Shi J-F, Ma L, Qiao Y, Ortendahl J, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer. 2010;127:1404–11.CrossRefPubMed Levin CE, Sellors J, Shi J-F, Ma L, Qiao Y, Ortendahl J, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer. 2010;127:1404–11.CrossRefPubMed
26.
go back to reference Canfell K, Shi J-FF, Lew J-BB, Walker R, Zhao F-HH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29(13):2487–94.CrossRefPubMed Canfell K, Shi J-FF, Lew J-BB, Walker R, Zhao F-HH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29(13):2487–94.CrossRefPubMed
27.
go back to reference Coupe VMH, Berkhof J, Verheijen RHM, Meijer CJLM. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG. 2007;114(4):416–24.CrossRefPubMed Coupe VMH, Berkhof J, Verheijen RHM, Meijer CJLM. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG. 2007;114(4):416–24.CrossRefPubMed
28.
go back to reference Legood R, Smith MA, Lew J-BB, Walker R, Moss S, Kitchener HHC, et al. Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: Economic analysis from NHS Sentinel Sites Study. BMJ. 2012;345, e7086.CrossRefPubMedPubMedCentral Legood R, Smith MA, Lew J-BB, Walker R, Moss S, Kitchener HHC, et al. Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: Economic analysis from NHS Sentinel Sites Study. BMJ. 2012;345, e7086.CrossRefPubMedPubMedCentral
29.
go back to reference Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, et al. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol. 2010;116:1158–70.CrossRefPubMed Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, et al. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol. 2010;116:1158–70.CrossRefPubMed
30.
go back to reference Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol. 2010;119(2):237–242. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol. 2010;119(2):237–242.
31.
go back to reference Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG. 2012;119(2):166–76.CrossRefPubMed Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG. 2012;119(2):166–76.CrossRefPubMed
32.
go back to reference Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107–15.CrossRefPubMed Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107–15.CrossRefPubMed
33.
go back to reference Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin CE, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.CrossRefPubMed Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin CE, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.CrossRefPubMed
34.
go back to reference Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues. 2010;20(1):35–42.CrossRefPubMed Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues. 2010;20(1):35–42.CrossRefPubMed
35.
go back to reference Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011;29:781–806.CrossRefPubMed Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011;29:781–806.CrossRefPubMed
36.
go back to reference Gutierrez-Delgado C, Baez-Mendoza C, Gonzalez-Pier E, de la Rosa AP, Witlen R. [Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective]. Salud Publica Mex. 2008;50:107–18.CrossRefPubMed Gutierrez-Delgado C, Baez-Mendoza C, Gonzalez-Pier E, de la Rosa AP, Witlen R. [Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective]. Salud Publica Mex. 2008;50:107–18.CrossRefPubMed
37.
go back to reference Chen M-KK, Hung H-FF, Duffy S, Yen AM-F, Chen H-HH. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. J Eval Clin Pract. 2011;17(6):1050–8.CrossRefPubMed Chen M-KK, Hung H-FF, Duffy S, Yen AM-F, Chen H-HH. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. J Eval Clin Pract. 2011;17(6):1050–8.CrossRefPubMed
38.
go back to reference Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;8:538–45.CrossRef Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;8:538–45.CrossRef
39.
go back to reference Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang K-L, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26 Suppl 5:F46–58.CrossRefPubMed Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang K-L, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26 Suppl 5:F46–58.CrossRefPubMed
40.
go back to reference Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine. 2008;10:76–86.CrossRef Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine. 2008;10:76–86.CrossRef
41.
go back to reference Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, et al. Calibrating Models in Economic Evaluation. 2011;29:35–49. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, et al. Calibrating Models in Economic Evaluation. 2011;29:35–49.
42.
go back to reference Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804.CrossRefPubMed Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804.CrossRefPubMed
43.
go back to reference Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;26 Suppl 3:F157–67.CrossRef Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;26 Suppl 3:F157–67.CrossRef
44.
go back to reference Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMed Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMed
45.
go back to reference Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013;185:13–4.CrossRef Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ. 2013;185:13–4.CrossRef
46.
go back to reference International Agency for Research on Cancer. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014. International Agency for Research on Cancer. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
47.
go back to reference Dijkstra MG, Snijders PJF, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJLM. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 2014;25:927–35.CrossRefPubMed Dijkstra MG, Snijders PJF, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJLM. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 2014;25:927–35.CrossRefPubMed
48.
go back to reference Castle PE, de Sanjosé S, Qiao Y-L, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012;30 Suppl 5:F117–22.CrossRefPubMed Castle PE, de Sanjosé S, Qiao Y-L, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012;30 Suppl 5:F117–22.CrossRefPubMed
49.
go back to reference Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30 Suppl 5:F100–6.CrossRefPubMed Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30 Suppl 5:F100–6.CrossRefPubMed
50.
go back to reference Brisson M, Van de Velde N, Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343–51.CrossRefPubMed Brisson M, Van de Velde N, Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343–51.CrossRefPubMed
51.
go back to reference Smith M, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. J Infect Dis. 2014;211(1):1–9. Oxford, UK. Smith M, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. J Infect Dis. 2014;211(1):1–9. Oxford, UK.
52.
go back to reference Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 8:I1–31.CrossRefPubMedPubMedCentral Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 8:I1–31.CrossRefPubMedPubMedCentral
53.
go back to reference Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7:38.CrossRefPubMedPubMedCentral Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7:38.CrossRefPubMedPubMedCentral
54.
go back to reference Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24 Suppl 3:S3–86. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24 Suppl 3:S3–86.
55.
go back to reference Joura E, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372:711–23.CrossRefPubMed Joura E, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372:711–23.CrossRefPubMed
56.
go back to reference De Blasio BF, Neilson AR, Klemp M, Skjeldestad FE. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J Public Health (Oxf) 2012;539–547. De Blasio BF, Neilson AR, Klemp M, Skjeldestad FE. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J Public Health (Oxf) 2012;539–547.
57.
go back to reference Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine. 2012;30(2):425–35.CrossRefPubMed Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine. 2012;30(2):425–35.CrossRefPubMed
58.
go back to reference Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:1043–53.CrossRefPubMed Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:1043–53.CrossRefPubMed
59.
go back to reference Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9–10, 2009. Clin Ther. 2010;32:1546–64.CrossRefPubMedPubMedCentral Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M. Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9–10, 2009. Clin Ther. 2010;32:1546–64.CrossRefPubMedPubMedCentral
Metadata
Title
Systematic review of model-based cervical screening evaluations
Authors
Diana Mendes
Iren Bains
Tazio Vanni
Mark Jit
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1332-8

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine